June 3, 2021 05:00 PM EDT
R&D

#AS­CO21: Mer­ck keeps chop­ping away at a path to ear­ly can­cer pa­tients for Keytru­da, this time in kid­ney

Kyle Blankenship

In the for­ev­er war be­tween block­buster check­point in­hibitors, Mer­ck’s won­der drug Keytru­da has tak­en a clear edge over its near­est ri­vals in metasta­t­ic, un­re­sectable can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times